Litak (cladribine)
- Region
- 🇪🇺 EU
- Active substance
- cladribine
- Company
- Lipomed GmbH
- Status
- Authorised
- Therapeutic area
- Leukemia, Hairy Cell
- EU approval
- Wed 14 Apr 2004
- Application
- EMEA/H/C/000504
- ATC
- L01BB04
- Official record
- www.ema.europa.eu
Indication
Litak is indicated for the treatment of hairy-cell leukaemia.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Mavenclad Authorised · Merck Europe B.V.
- 🇪🇺 Movectro Application withdrawn · Merck Serono Europe Limited
Follow Litak
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.